ENLV: חוב לטווח קצר של החברה Enlivex Therapeutics Ltd

Renowned scientists within the leadership of Enlivex Therapeutics (ENLV) guarantee trial transparency and strict adherence to protocols. The volume of short-term borrowed capital reflects solvency dynamics, where the 0.00 metric determines this level. Management is implementing innovations in the treatment of sepsis and cancer, establishing new therapy standards. However, the lack of internal cash flow makes development dependent on external financing.

This indicator measures the current load of obligations maturing within one year, allowing for an assessment of liquidity risk and the cost of debt service amid rate volatility. The current value of 0.00 demonstrates the financial stability of Enlivex Therapeutics (ENLV) as it develops a unique macrophage reprogramming system to combat sepsis, which clearly reflects the short-term debt trend.